Pyoderma Gangrenosum clinical trials
The registry lists 36 studies for Pyoderma Gangrenosum across more than 10 countries. 7 are recruiting or about to start. 33 of them are mainly about Pyoderma Gangrenosum (how this is decided). Per ClinicalTrials.gov, last updated 2026-11-09.
Get an email when these change. Save the Pyoderma Gangrenosum studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your saved searches, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your saved searches. Stop any time.
Who runs them
Oregon Health and Science University (4) · XOMA (US) LLC (4) · Ohio State University (2) · University of Zurich (2) · AbbVie (2) · Wake Forest University Health Sciences (2) · InflaRx GmbH (2) · LEO Pharma (1)
What is being tested here
Drugs under test in Pyoderma Gangrenosum studies, those with the most open studies first. Medicines only given beside them are not counted. How drugs are counted
| Drug | Open | Phase 3 | All |
|---|---|---|---|
| SHR-1139 | 2 | 0 | 2 |
| Spesolimab | 1 | 1 | 2 |
| Oxygen | 1 | 0 | 1 |
| Bimekizumab | 1 | 0 | 1 |
| Ruxolitinib | 1 | 0 | 1 |
| Gevokizumab | 0 | 3 | 4 |
| Adalimumab | 0 | 1 | 3 |
| Vilobelimab | 0 | 1 | 2 |
| Secukinumab | 0 | 0 | 2 |
| Guselkumab | 0 | 0 | 1 |
Drug classes tested here JAK inhibitors 1 open · Tyrosine kinase inhibitors (TKIs) 1 open
Coming up
Studies recruiting or running, from their records. “Main data collection” ends at the primary completion date, the sponsor’s own estimate, which often moves.
All 3, phase 3 first
- Nov 2027A Study to Test Whether Spesolimab Helps People With a Skin Condition Called Pyoderma Gangrenosum · Phase 3 · LEO Pharma
- Jun 2027A Study to Evaluate SHR-1139 Injection in Patients With Pyoderma Gangrenosum · Guangdong Hengrui Pharmaceutical Co., Ltd
- Aug 2027Guselkumab in the Treatment of Adults With Pyoderma Gangrenosum (PG) · Oregon Health and Science University
Who these studies take
Of the 4 Pyoderma Gangrenosum studies recruiting now, 3 (75%) set no upper age limit and 0 (0%) stop at 75 or younger. 1 (25%) take children under 18. 0 (0%) are for women only and 0 (0%) for men only; 0 (0%) take healthy volunteers.
| Age | Women | Men |
|---|---|---|
| 10 | 1 (25%) | 1 (25%) |
| 18 | 4 (100%) | 4 (100%) |
| 30 | 4 (100%) | 4 (100%) |
| 40 | 4 (100%) | 4 (100%) |
| 50 | 4 (100%) | 4 (100%) |
| 65 | 4 (100%) | 4 (100%) |
| 75 | 4 (100%) | 4 (100%) |
| 85 | 4 (100%) | 4 (100%) |
Across all 36 studies, recruiting or not: 11% stop at 75 or younger and 0% at 65; 17% take children; 0% are for women only and 0% for men only; 6% take healthy volunteers. From each study’s registry entry; the criteria on its page decide.
Studies
Recruiting first, then most recently updated. Showing 36 of 36. search them.
- A Study to Test Whether Spesolimab Helps People With a Skin Condition Called Pyoderma GangrenosumRecruitingNCT06624670Phase 321 countries
- Topical Ruxolitinib in the Treatment of Adults With Pyoderma GangrenosumRecruitingNCT07783412Phase 21 country
- Emerging Indications for Hyperbaric Oxygen TreatmentNot yet recruitingNCT07240649Phase 4
- A Clinical Study Evaluating the Efficacy and Safety of SHR-1139 Injection in Adult Patients With Ulcerative Pyoderma GangrenosumRecruitingNCT07337564Phase 21 country
- Efficacy of Bimekizumab in Adults With Pyoderma GangrenosumNot yet recruitingNCT07767864Phase 21 country
- A Study to Evaluate SHR-1139 Injection in Patients With Pyoderma GangrenosumNot yet recruitingNCT07444684Phase 21 country
- A Real-World Registry of Chronic Wounds and UlcersRecruitingNCT022807331 country
- Guselkumab in the Treatment of Adults With Pyoderma Gangrenosum (PG)Active, not recruitingNCT06563323Phase 21 country
- Spesolimab in Pyoderma GangrenosumTerminatedNCT06092216Phase 21 country
- Phase III Trial to Investigate Efficacy and Safety of Vilobelimab in Ulcerative Pyoderma GangrenosumTerminatedNCT05964413Phase 310 countries
- A Novel Therapeutic Treatment of Pyoderma GangrenosumTerminatedNCT05120726Phase 41 country
- Autologous Platelet-Rich Plasma Therapy in the Treatment of Pyoderma GangrenosumWithdrawnNCT05984654Not applicable1 country
- A Study to Assess Adverse Events and Change in Disease State in Adult Participants Being Treated With Humira in Participants Diagnosed With Pyoderma Gangrenosum (PG)CompletedNCT047502131 country
- A Phase II Open Label Study of Xilonix in Subjects With Pyoderma GangrenosumCompletedNCT01965613Phase 21 country
- Deucravacitinib in PGWithdrawnNCT05821374Early Phase 11 country
- Baricitinib in the Treatment of Adults With Pyoderma Gangrenosum (PG)CompletedNCT04901325Phase 21 country
- Hyperbaric Oxygen Therapy for Pyoderma GangrenosumTerminatedNCT05343754Phase 31 country
- An Open-Label, Proof-of-Concept Study of Ixekizumab in the Treatment of Pyoderma GangrenosumCompletedNCT03137160Phase 21 country
- Exploratory Study of IFX-1 in Patients With Pyoderma GangrenosumCompletedNCT03971643Phase 23 countries
- Single-arm Study to Assess a Potential Effect of Anti-IL-17 (Secukinumab) in the Treatment of Pyoderma GangrenosumCompletedNCT02733094Phase 1/21 country
- Phase 0/1 Local Application of the Monoclonal Antibody (Mab) sB24M in Patients With Purulent PyodermaCompletedNCT04895566Early Phase 12 countries
- JAK-STAT Signaling Pathway in Pyoderma GangrenosumStatus unknownNCT04792957
- Safety and Efficacy Study of Humira in Treatment of Pyoderma GangrenosumWithdrawnNCT00730717Phase 21 country
- Efficacy and Safety of APD334 in Patients With Pyoderma GangrenosumTerminatedNCT03072953Phase 22 countries
- Secukinumab for the Inflammatory Phase of Pyoderma GangrenosumWithdrawnNCT04274166Phase 2
- A Study Assessing the Efficacy and Safety of Adalimumab in Active Ulcer(s) of Pyoderma Gangrenosum in Participants in JapanCompletedNCT03311464Phase 31 country
- Study to Determine the Safety and Efficacy of Adalimumab in the Treatment of Pyoderma GangrenosumWithdrawnNCT00690846Phase 21 country
- Study on the Clinical Features, Comorbidities and Pathologies Associated With Pyoderma GangrenosumStatus unknownNCT036367371 country
- Open Label Study for Adults With Pyoderma Gangrenosum and Inflammatory Bowel DiseaseCompletedNCT00791557Not applicable1 country
- Canakinumab for Pyoderma GangrenosumCompletedNCT01302795Phase 21 country
- Observational Study of the Genetic Architecture of Neutrophil-Mediated Inflammatory Skin DiseasesStatus unknownNCT019522751 country
- An Efficacy and Safety Study of Gevokizumab in Treating Active Ulcers of Pyoderma GangrenosumTerminatedNCT02326740Phase 33 countries
- An Efficacy and Safety Study of Gevokizumab in Treating Active Ulcers of Pyoderma GangrenosumTerminatedNCT02315417Phase 31 country
- A 2-Year, Open-Label, Safety Extension Study of Gevokizumab in Subjects With Pyoderma GangrenosumTerminatedNCT02318914Phase 33 countries
- Proof of Concept Study of Gevokizumab in the Treatment of Pyoderma GangrenosumCompletedNCT01882504Phase 21 country
- Topical Tacrolimus 0.1% Ointment For Treatment Of Cutaneous Crohn's DiseaseCompletedNCT01233570Phase 21 country